Improvement of HbA(1c) and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps

Diabetes Care

Volumn 21, Issue 6, 1998, Pages 977-982

  Melki, Vincent ^a,h   Renard, Eric ^b   Lassmann Vague, Véronique ^c   Boivin, Sophie ^d   Guerci, Bruno ^e   Hanaire Broutin, Hélène ^a   Bringer, Jacques ^b   Belicar, Pauline ^c   Jeandidier, Nathalie ^d   Meyer, Laurent ^e   Blin, Patrick ^f   Augendre Ferrante, Béatrice ^g   Tauber, Jean Pierre ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c TIMONE HOSPITAL   (France)

^d HÔPITAL CIVIL   (France)

^e Ctr Hospitalier Univ de Nancy   (France)

^f EVAL   (France)

^g Lilly France   (France)

^h CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; INSULIN LISPRO; MONOCOMPONENT INSULIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN, NEUTRAL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MALE; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED DISORDER; INSULIN INFUSION; METABOLISM; MULTICENTER STUDY; PATIENT SATISFACTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; PATIENT SATISFACTION; QUESTIONNAIRES;

EID: 0032086121     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.6.977     Document Type: Article

References (25)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mcllitus. N Engl J Med 329:977-986, 1993
2. The Diabetes Control and Complication Trial Research Group: Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 18:361-376, 1995
3. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial, Diabetes 46:271-286,1997
4. Bode BW, Steed RD, Davidson PC: Reduction in severe hypoglycemia with long-term subcutaneous insulin infusion in type I diabetes. Diabetes Care 19:324-327,1996
5. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF; Ganes T, Kierulf P, Smeland E, Sandvik L, Aagenaes O: Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo Study Br Med J (Clin Res Ed) 293:1195-1199, 1986
6. Vaag A, Handberg A, Lauritzen M, Henriksen JE, Pedersen KD, Beck-Nielsen H: Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 13:74-76, 1990
7. Christiansen JS, Lauritzen T: Pharmacokinetic aspects of insulin therapy- with special reference to pumps and pens versus conventional treatment. In Pharmacology of Diabetes: Present Practice and Future Perspectives. Mogensen CE, Standl E, Eds. Berlin, de Gruyter, 1991, p. 23-38
8. Gardner DF; Arakaki RE Podet EJ, Nell LJ, Thomas JW, Field JB: The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessment using a glucose clamp technique. J Clin Endocrinol Metab 63:689-694, 1986
9. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys (B28), Pro (B29)]human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
10. Pfützner A, Küstner E, Forst T, SchulzeSchleppinhoff B, Trautmann ME, Haslbeck M, Schatz H, BeyerJ: Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemie episodes. Exp Clin Endocrinol 104:25-30, 1996
11. Brunelle RL, Anderson JH, Vignati L: Decreased rate of hypoglycemia in association with improved metabolic control with lispro insulin (Abstract). Diabetologia 37 (Suppl. 1):A78, 1994
12. Anderson JH, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R, the Multicenter Insulin Lispro Study Group; Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 46:265-270,1997
13. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH, the BeneluxUK Insulin Lispro Study Group: Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro, Diabetes Care 20:1827-1832, 1997
14. Vignati L, Anderson JH, Brunelle RL, Jefferson FL, Richardson M: Improvement of glycemie control with the rapidly absorbed lispro insulin analog in type 1 diabetes (Abstract). Diabctologa 37 (Suppl. 1):A78, 1994
15. Ebeling P, Jansson P-A, Smith U, Lalli C, Bolli GB, Koivisto VA: Strategies toward improved control during insulin lispro therapy in IDDM. Diabetes Care 20:1287-1289, 1997
16. Del Sindaco P, Ciofetta M, Torlone E, Perriello G, Brunetti P, Bolli GB: Importance of basal insulin to improve control without increasing hypoglycemia in intensively treated IDDM using a short-acting insulin analog at meals (Abstract). Diabetologa 40 (Suppl. 1):A352, 1997
17. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T: Insulin lispro in CSII: results of double-blind crossover study Diabetes 46:440-443, 1997
18. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S: Immunologie effects of insulin lispro [Lys (28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 45:1750-1754, 1996
19. Tauber JP: Insulin analog (Humalog) in discontinuous injections: from pharmacology to clinical use. Diabetes Metab 23:50-57, 1997
20. 1c.) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
21. Antsiferov M, Woodworth JR, Mayarov A, Ristic S, Dedov I: Within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin. Diabetologia 38 (Suppl. 1):A190, 1995
22. Broussolle C, Jeandidier N, HanaireBroutin H: French multicenter experience of implantable insulin pumps. Lancet 343:514-515, 1994
23. Castillo MJ, Scheen AJ, Lefebvre P: The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose level. J Clin Endocrinol Metab 81:1975-1978, 1996
24. Pein M, Hinseimann C, Pfutzner A, Dreyer M: Catheter disconnection in type 1-diabetic patients treated with CSII: comparison of insulin lispro and human regular insulin (Abstract). Diabetologia 39 (Suppl. 1):A223, 1996
25. Pfüizner A, Renner R, the German Huma- log CSII Study Group; CSII therapy with insulin pumps using insulin lispro, Diabetes 46 (Suppl. 1):34A, 1997